Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

Chromium consumables revenue was $118.1 million ... Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results with substantial ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Chromium Consumables Revenue (Q4 2024): $97.7 million ... Revenue Guidance (2025): $610 million to $630 million, representing ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...